Hydroxyapatite based drug delivery implant for cancer treatment
US6767550B1 · kind B1 · utility
22Cited by
5References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 30, 2000 |
| Grant date | Jul 27, 2004 |
| Priority date | — |
| Expiry date | Jun 30, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/2009
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A hydroxyapatite based bioresorbable material is incorporated with anti-cancer agents to form an implant used for treatment against cancer. Sustained release of the anti-cancer agents may be achieved after implantation at the targeted sites. The dosage of the anti-cancer agent, the microstructure, morphology, and composition of the bioresorbable material allow control of the release profile. The invented implant may be used for drug delivery, chemotherapy, or gene therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.